1.84
+2.22%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eastwood Bio-Medical Canada
Its shares trade on TSX Venture under the ticker EBM.V. It has been listed since 5 September 2014. In the fiscal year to 31 October 2025, it reported revenue of C$782,080 and a net loss of C$332,767. At that date it held total assets of C$218,772 and shareholders' equity of −C$1.6m.
Eastwood Bio-Medical Canada, Inc. is a natural health supplement distribution company. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-09-05. The company is a licensed distributor of the Eleotin line of products, which include formulations based on natural ingredients that are presented in tea or capsule forms. The Eleotin products include natural remedies for certain metabolic disorders such as blood glucose disorders, hypertension and obesity, and can be used as a dietary supplement. Its licensed products include Eleotin A 700, which is a treatment for spleen deficiency, lack of appetite and fatigue; Eleotin AL88, a laxative; Eleotin Cal20, for bone and teeth maintenance; Eleotin V3D, for the development and maintenance of bones, teeth and good health; Eleotin G2000, for cardiovascular health; Eleotin H55, for sedative and tension relief, and Eleotin Zn330, for the tissue formation and metabolism. In addition, it offers Eleotin Bentley to promote healthy glucose levels and Eleotin LBM for hypertension relief.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 5 Sept 2014
- Website
- eleotin.ca ↗
Leadership
Pay as last reported
- Ms. Yunji KimPresident, Chief Financial Officer, Corporate Secretary, Director, since 2012C$36,074
- Dr. Youngsoo KimChief Executive Officer, Director, since 2020C$31,253
- Dr. Marcus KuypersIndependent Director$1,000
- Mr. Ian MallmannIndependent Director, since 2019C$4,000
- Dr. Terrance OwenIndependent Director$1,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Natural health supplement distribution company with licensed Eleotin products for metabolic disorders.
- Eleotin A 700 treats spleen deficiency and fatigue with natural ingredients.
- Eleotin G2000 supports cardiovascular health through natural dietary supplements.
Weaknesses
- Eleotin AL88 functions as a laxative without additional health benefits.
- Eleotin Cal20 focuses solely on bone and teeth maintenance without broader applications.
- Eleotin V3D targets bone and teeth development but lacks additional health claims.
Opportunities
- Expanding Eleotin Bentley for healthy glucose levels in the Canadian market.
- Introducing Eleotin LBM for hypertension relief to new segments.
- Growing Eleotin Zn330 for tissue formation and metabolism globally.
Threats
- Eleotin H55 provides sedative effects but may face regulatory scrutiny in Health Care sector.
- Eleotin G2000 competes with established cardiovascular supplements in Health Care.
- Eleotin V3D lacks differentiation in the crowded bone and teeth health market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.